Home>Topics>Stocks>Exelixis

Exelixis EXEL

  1. All
  2. Commentary
  3. Headlines
    1. Exelixis 3Q Results as Expected; Maintaining FVE

      Commentary

      Wed, 5 Nov 2014

      Exelixis reported in-line third-quarter results and positive Phase II data for Cometriq ..... the clinical trial and the company’s rapidly dwindling cash reserves, Exelixis faces an uncertain future. Cometriq revenue for the quarter was $6.3

    2. Cobimetinib Combo Results are Positive, but Melanoma Landscape Is Becoming More Challenging

      Commentary

      Mon, 29 Sep 2014

      Exelixis and partner Roche reported positive detailed results for their Phase III study of MEK inhibitor cobimetinib in combination with

    3. UPDATE 1-Roche, GSK melanoma pill combinations look similar in showdown

      Headlines

      Mon, 29 Sep 2014

      * Shares in Roche's biotech partner Exelixis jump 20 pct (Adds Exelixis share price jump, more on treatment debate)

    4. Exelixis Fails in Key Prostate Cancer Trial; Dramatically Lowering Fair Value Estimate

      Commentary

      Tue, 2 Sep 2014

      Exelixis announced Monday that its key Phase III COMET-1 trial in men with metastatic ..... statistically significant (p value of 0.21). Based on the trial result, Exelixis plans to halt its clinical program in prostate cancer and reduce its workforce

    5. Exelixis' 2Q Results In Line; Phase III Prostate Cancer Results Later This Year Remain Key Driver

      Commentary

      Fri, 1 Aug 2014

      Exelixis reported second-quarter results that were generally consistent with our ..... year and represent the major catalysts for the firm. During the quarter, Exelixis and partner Roche announced positive top-line results for their Phase

    6. Positive Phase III Results With Roche-Partnered Program; Cometriq Trials Remain Key Driver

      Commentary

      Mon, 14 Jul 2014

      Exelixis and partner Roche have announced positive top-line results for their Phase ..... 50 per share fair value estimate and no-moat, stable trend rating for Exelixis , as we continue to await the more important Phase III results for Cometriq

    7. EXEL - Coming back or a dog?

      Commentary

      Thu, 10 Jul 2014

      Not much news on this one lately, depsite a big drop following Morningstar's latest reaffirmation.  Still a Monringstar 5-star, but lots of shorts and mixed thoughts across traders.  Just bought in at 3 and a quarter, so we'll see.  Speculative at best at this point.  

    8. Exelixis 1Q Results as Expected; Phase III Prostate Cancer Results in 2014 Remain Key Driver

      Commentary

      Fri, 2 May 2014

      Exelixis reported first-quarter results that were generally consistent with our ..... this year and represent the major catalysts for the firm. In addition, Exelixis ’ partnered asset with Roche, MEK inhibitor GDC-0973 (in combination

    9. Is This the Year Exelixis Excels?

      Headlines

      Fri, 28 Mar 2014

      Exelixis EXEL announced this week that after a prespecified ..... value estimate and no-moat rating for Exelixis . While the stock had been trading around ..... later in 2014. Product Pipeline Is Full Exelixis is best known for its R&D prowess for

    10. Overreaction to Exelixis' Lack of Early Success in Cancer Trial Provides Attractive Opportunity

      Commentary

      Wed, 26 Mar 2014

      Exelixis announced Tuesday that after a prespecified interim analysis for Cometriq ..... are maintaining our $7.50 fair value estimate and no-moat rating for Exelixis . While the stock was recently trading around our fair value estimate

    « Prev12345Next »
    Content Partners